Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis
Background & Aims It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. Methods Pat...
Gespeichert in:
Veröffentlicht in: | Clinical gastroenterology and hepatology 2011-06, Vol.9 (6), p.483-489.e3 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 489.e3 |
---|---|
container_issue | 6 |
container_start_page | 483 |
container_title | Clinical gastroenterology and hepatology |
container_volume | 9 |
creator | Ardizzone, Sandro Cassinotti, Andrea Duca, Piergiorgio Mazzali, Cristina Penati, Chiara Manes, Gianpiero Marmo, Riccardo Massari, Alessandro Molteni, Paola Maconi, Giovanni Porro, Gabriele Bianchi |
description | Background & Aims It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. Methods Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel–Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0–1; Baron, 0), partial (group B: PT, 0–1; Baron, 1–3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed. Results After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21–6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67–25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24–32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12–6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193–51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556–8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278–55.186; P = .0268). Conclusions No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course. |
doi_str_mv | 10.1016/j.cgh.2010.12.028 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_869404520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1542356510013431</els_id><sourcerecordid>869404520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-d1981c2101cfa69475fe8f5543bd549b6c3f769129d75cebc39c080ec2847b793</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhSMEoqXwA7gg3zjt1nbiJBYSUrVQWmmhSNCz5UwmWy_euPU4rfbf42gXDhw4eax570nzvaJ4K_hScFGfb5ewuVtKPv_lksv2WXEqVCUXTSOq58e5VLU6KV4RbTmXutLNy-JECqFVo-vT4unrBIGsZ1dovRs37HvE3kEitrYJ2c2UIOyQ2MWQMLJ0h-zSRUpsFaZIyMKQp5hczsj74HpiQ4jsGz75Pfvk7GYMhD279YDRJveIWe5dcvS6eDFYT_jm-J4Vt5eff66uFuubL9eri_UClKjTohe6FSDztTDYWleNGrAdlKrKrleV7mooh6bWQuq-UYAdlBp4yxFkWzVdo8uz4v0h9z6GhwkpmZ0jQO_tiGEi0-ZQXinJs1IclBADUcTB3Ee3s3FvBDczbrM1GbeZcRshTcadPe-O6VO3w_6v4w_fLPhwEGC-8dFhNAQOR8iMI0IyfXD_jf_4jxtyRw6s_4V7pG3uYMzwjDCUDebH3Pdct-BclFUpyt-rxqWz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>869404520</pqid></control><display><type>article</type><title>Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Ardizzone, Sandro ; Cassinotti, Andrea ; Duca, Piergiorgio ; Mazzali, Cristina ; Penati, Chiara ; Manes, Gianpiero ; Marmo, Riccardo ; Massari, Alessandro ; Molteni, Paola ; Maconi, Giovanni ; Porro, Gabriele Bianchi</creator><creatorcontrib>Ardizzone, Sandro ; Cassinotti, Andrea ; Duca, Piergiorgio ; Mazzali, Cristina ; Penati, Chiara ; Manes, Gianpiero ; Marmo, Riccardo ; Massari, Alessandro ; Molteni, Paola ; Maconi, Giovanni ; Porro, Gabriele Bianchi</creatorcontrib><description>Background & Aims It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. Methods Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel–Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0–1; Baron, 0), partial (group B: PT, 0–1; Baron, 1–3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed. Results After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21–6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67–25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24–32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12–6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193–51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556–8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278–55.186; P = .0268). Conclusions No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2010.12.028</identifier><identifier>PMID: 21195796</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adrenal Cortex Hormones - administration & dosage ; Adult ; Anti-Inflammatory Agents - administration & dosage ; Clinical Course ; Colitis, Ulcerative - drug therapy ; Colitis, Ulcerative - pathology ; Drug Monitoring - methods ; Endoscopy ; Female ; Follow-Up Studies ; Gastroenterology and Hepatology ; Humans ; Inflammatory Bowel Diseases ; Intestinal Mucosa - pathology ; Male ; Middle Aged ; Mucosal Healing ; Prognosis ; Treatment Outcome</subject><ispartof>Clinical gastroenterology and hepatology, 2011-06, Vol.9 (6), p.483-489.e3</ispartof><rights>AGA Institute</rights><rights>2011 AGA Institute</rights><rights>Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-d1981c2101cfa69475fe8f5543bd549b6c3f769129d75cebc39c080ec2847b793</citedby><cites>FETCH-LOGICAL-c516t-d1981c2101cfa69475fe8f5543bd549b6c3f769129d75cebc39c080ec2847b793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2010.12.028$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21195796$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ardizzone, Sandro</creatorcontrib><creatorcontrib>Cassinotti, Andrea</creatorcontrib><creatorcontrib>Duca, Piergiorgio</creatorcontrib><creatorcontrib>Mazzali, Cristina</creatorcontrib><creatorcontrib>Penati, Chiara</creatorcontrib><creatorcontrib>Manes, Gianpiero</creatorcontrib><creatorcontrib>Marmo, Riccardo</creatorcontrib><creatorcontrib>Massari, Alessandro</creatorcontrib><creatorcontrib>Molteni, Paola</creatorcontrib><creatorcontrib>Maconi, Giovanni</creatorcontrib><creatorcontrib>Porro, Gabriele Bianchi</creatorcontrib><title>Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Background & Aims It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. Methods Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel–Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0–1; Baron, 0), partial (group B: PT, 0–1; Baron, 1–3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed. Results After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21–6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67–25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24–32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12–6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193–51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556–8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278–55.186; P = .0268). Conclusions No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course.</description><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Adult</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Clinical Course</subject><subject>Colitis, Ulcerative - drug therapy</subject><subject>Colitis, Ulcerative - pathology</subject><subject>Drug Monitoring - methods</subject><subject>Endoscopy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology and Hepatology</subject><subject>Humans</subject><subject>Inflammatory Bowel Diseases</subject><subject>Intestinal Mucosa - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mucosal Healing</subject><subject>Prognosis</subject><subject>Treatment Outcome</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFv1DAQhSMEoqXwA7gg3zjt1nbiJBYSUrVQWmmhSNCz5UwmWy_euPU4rfbf42gXDhw4eax570nzvaJ4K_hScFGfb5ewuVtKPv_lksv2WXEqVCUXTSOq58e5VLU6KV4RbTmXutLNy-JECqFVo-vT4unrBIGsZ1dovRs37HvE3kEitrYJ2c2UIOyQ2MWQMLJ0h-zSRUpsFaZIyMKQp5hczsj74HpiQ4jsGz75Pfvk7GYMhD279YDRJveIWe5dcvS6eDFYT_jm-J4Vt5eff66uFuubL9eri_UClKjTohe6FSDztTDYWleNGrAdlKrKrleV7mooh6bWQuq-UYAdlBp4yxFkWzVdo8uz4v0h9z6GhwkpmZ0jQO_tiGEi0-ZQXinJs1IclBADUcTB3Ee3s3FvBDczbrM1GbeZcRshTcadPe-O6VO3w_6v4w_fLPhwEGC-8dFhNAQOR8iMI0IyfXD_jf_4jxtyRw6s_4V7pG3uYMzwjDCUDebH3Pdct-BclFUpyt-rxqWz</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Ardizzone, Sandro</creator><creator>Cassinotti, Andrea</creator><creator>Duca, Piergiorgio</creator><creator>Mazzali, Cristina</creator><creator>Penati, Chiara</creator><creator>Manes, Gianpiero</creator><creator>Marmo, Riccardo</creator><creator>Massari, Alessandro</creator><creator>Molteni, Paola</creator><creator>Maconi, Giovanni</creator><creator>Porro, Gabriele Bianchi</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110601</creationdate><title>Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis</title><author>Ardizzone, Sandro ; Cassinotti, Andrea ; Duca, Piergiorgio ; Mazzali, Cristina ; Penati, Chiara ; Manes, Gianpiero ; Marmo, Riccardo ; Massari, Alessandro ; Molteni, Paola ; Maconi, Giovanni ; Porro, Gabriele Bianchi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-d1981c2101cfa69475fe8f5543bd549b6c3f769129d75cebc39c080ec2847b793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Adult</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Clinical Course</topic><topic>Colitis, Ulcerative - drug therapy</topic><topic>Colitis, Ulcerative - pathology</topic><topic>Drug Monitoring - methods</topic><topic>Endoscopy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology and Hepatology</topic><topic>Humans</topic><topic>Inflammatory Bowel Diseases</topic><topic>Intestinal Mucosa - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mucosal Healing</topic><topic>Prognosis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ardizzone, Sandro</creatorcontrib><creatorcontrib>Cassinotti, Andrea</creatorcontrib><creatorcontrib>Duca, Piergiorgio</creatorcontrib><creatorcontrib>Mazzali, Cristina</creatorcontrib><creatorcontrib>Penati, Chiara</creatorcontrib><creatorcontrib>Manes, Gianpiero</creatorcontrib><creatorcontrib>Marmo, Riccardo</creatorcontrib><creatorcontrib>Massari, Alessandro</creatorcontrib><creatorcontrib>Molteni, Paola</creatorcontrib><creatorcontrib>Maconi, Giovanni</creatorcontrib><creatorcontrib>Porro, Gabriele Bianchi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ardizzone, Sandro</au><au>Cassinotti, Andrea</au><au>Duca, Piergiorgio</au><au>Mazzali, Cristina</au><au>Penati, Chiara</au><au>Manes, Gianpiero</au><au>Marmo, Riccardo</au><au>Massari, Alessandro</au><au>Molteni, Paola</au><au>Maconi, Giovanni</au><au>Porro, Gabriele Bianchi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>9</volume><issue>6</issue><spage>483</spage><epage>489.e3</epage><pages>483-489.e3</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Background & Aims It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. Methods Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel–Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0–1; Baron, 0), partial (group B: PT, 0–1; Baron, 1–3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed. Results After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21–6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67–25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24–32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12–6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193–51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556–8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278–55.186; P = .0268). Conclusions No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21195796</pmid><doi>10.1016/j.cgh.2010.12.028</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1542-3565 |
ispartof | Clinical gastroenterology and hepatology, 2011-06, Vol.9 (6), p.483-489.e3 |
issn | 1542-3565 1542-7714 |
language | eng |
recordid | cdi_proquest_miscellaneous_869404520 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Adrenal Cortex Hormones - administration & dosage Adult Anti-Inflammatory Agents - administration & dosage Clinical Course Colitis, Ulcerative - drug therapy Colitis, Ulcerative - pathology Drug Monitoring - methods Endoscopy Female Follow-Up Studies Gastroenterology and Hepatology Humans Inflammatory Bowel Diseases Intestinal Mucosa - pathology Male Middle Aged Mucosal Healing Prognosis Treatment Outcome |
title | Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T19%3A56%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mucosal%20Healing%20Predicts%20Late%20Outcomes%20After%20the%20First%20Course%20of%20Corticosteroids%20for%20Newly%20Diagnosed%20Ulcerative%20Colitis&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Ardizzone,%20Sandro&rft.date=2011-06-01&rft.volume=9&rft.issue=6&rft.spage=483&rft.epage=489.e3&rft.pages=483-489.e3&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2010.12.028&rft_dat=%3Cproquest_cross%3E869404520%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=869404520&rft_id=info:pmid/21195796&rft_els_id=1_s2_0_S1542356510013431&rfr_iscdi=true |